Streptococcosis in Farmed Tilapia: Diagnosis, Vaccination Strategies, and Outbreak Management

Introduction

Streptococcosis is a major bacterial disease affecting farmed tilapia (Oreochromis spp.) worldwide, responsible for substantial economic losses in both freshwater and brackish water aquaculture systems. The disease is primarily caused by two Gram-positive cocci: Streptococcus agalactiae (Lancefield group B) and Streptococcus iniae. Both pathogens share overlapping clinical presentations but differ in serotype distribution, virulence gene repertoire, and host tropism [1, 2]. The global expansion of tilapia farming, coupled with high stocking densities and water temperature fluctuations, has increased the incidence of streptococcal outbreaks [3]. This article provides a technical review of diagnostic methods including quantitative PCR (qPCR), commercial and experimental vaccination platforms, and evidence-based outbreak management protocols.

Etiology and Pathogenesis

Streptococcus agalactiae is a beta-hemolytic, catalase-negative coccus that possesses a polysaccharide capsule and expresses several virulence factors including CAMP factor, hyaluronidase, and the surface-anchored proteins Sip and BibA [4]. In tilapia, serotype Ia and Ib are most frequently isolated, although serotype III strains have also been reported [5]. Streptococcus iniae is also beta-hemolytic and produces a polysaccharide capsule, along with the exotoxins streptolysin S and a phosphoglucomutase required for capsule biosynthesis [6]. Infection occurs through the gills, skin abrasions, or the gastrointestinal tract after ingestion of contaminated feed or water [7].

Once inside the host, both species evade phagocytosis through capsule-mediated inhibition of complement deposition and opsonophagocytosis [8]. S. agalactiae can survive within macrophages by resisting oxidative killing, a mechanism partially dependent on superoxide dismutase and arginine deiminase pathways [9]. Systemic dissemination leads to septicemia, meningoencephalitis, and exophthalmia. The incubation period varies with water temperature: at 28 to 32 °C, clinical signs appear within 3 to 7 days post exposure [10].

Clinical Signs and Gross Pathology

Affected tilapia present with lethargy, anorexia, erratic swimming (spiraling or corkscrew motion), exophthalmia (unilateral or bilateral), corneal opacity, and abdominal distension [11]. Petechial hemorrhages may be observed on the opercula, ventral body surface, and around the anus. Mortality rates can reach 50 to 80 percent in untreated populations [12].

Necropsy findings typically include:

• Serosanguinous fluid in the peritoneal cavity.
• Hepatomegaly and splenomegaly with congestion.
• Meningeal hyperemia and hemorrhagic encephalomalacia.
• Focal necrosis in the liver, spleen, and kidney.
• Presence of a fibrinous exudate covering visceral organs [13, 14].

Histopathology reveals multifocal necrotizing hepatitis, splenitis, and interstitial nephritis. In the brain, perivascular cuffing, gliosis, and meningeal infiltration of mononuclear cells are characteristic [15].

Diagnostic Approaches

Conventional Bacteriology

Isolation is performed on blood agar or selective media such as modified Edwards medium supplemented with colistin and oxolinic acid [16]. Colonies appear as small, grayish, beta-hemolytic after 24 to 48 hours at 28 °C. Identification relies on Gram stain, catalase negativity, and pyrrolidonyl arylamidase (PYR) testing: S. iniae is PYR positive while S. agalactiae is PYR negative [17]. Lancefield serotyping can further differentiate group B streptococci.

Molecular Diagnostics

Quantitative PCR (qPCR) has become the gold standard for rapid detection and quantification of both species in brain, kidney, and spleen tissues. A multiplex qPCR targeting the cfb gene (CAMP factor) for S. agalactiae and the 16S rRNA gene for S. iniae achieves a limit of detection of 10 colony-forming units per gram of tissue [18]. A second panel using the surface immunogenic protein (sip) gene for S. agalactiae and the lactate oxidase (lctO) gene for S. iniae provides species-level discrimination in mixed infections [19].

For environmental surveillance, water samples are concentrated by filtration (0.45 µm membrane) followed by DNA extraction and qPCR. This method can detect as few as 10 bacterial cells per liter, enabling early warning before clinical onset [20].

Serological Assays

Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus illustrates the principle of antigen capture that has been adapted for tilapia streptococcosis. A monoclonal antibody-based sandwich ELISA targeting the S. agalactiae capsular polysaccharide shows 95 percent sensitivity and 98 percent specificity compared to culture [21]. For S. iniae, a polyclonal antibody ELISA against whole-cell antigens is available but shows cross-reactivity with Lactococcus garvieae [22].

Table 1: Comparison of diagnostic methods for streptococcosis in tilapia

Loop-mediated isothermal amplification (LAMP) has been developed as a field-deployable alternative. A LAMP assay targeting the manganese-dependent superoxide dismutase gene (sodA) can be performed using a simple heat block at 63 °C for 60 minutes, with results visualized by color change [23].

Vaccination Strategies

Bacterins and Inactivated Vaccines

Formalin-inactivated whole-cell bacterins (0.5% formalin, 24 h at 4 °C) adjuvanted with Freund's incomplete adjuvant or mineral oil have been widely used. Intraperitoneal injection of 10^8 colony-forming units per fish yields a relative percent survival (RPS) of 60 to 75 percent against homologous challenge [24]. The main limitation is serotype specificity: bacterins protect poorly against heterologous S. agalactiae serotypes [25].

Live Attenuated Vaccines

A temperature-sensitive mutant of S. agalactiae (ts-1) with a deletion in the relA gene confers protection after a single oral dose of 10^7 CFU per fish, achieving RPS values of 80 to 90 percent against both homologous and heterologous challenges [26]. A S. iniae mutant lacking the capsule biosynthetic cpsA gene is also protective but requires booster administration via immersion [27].

Recombinant Subunit Vaccines

Recombinant proteins such as the surface immunogenic protein (Sip), alpha-like protein (Alp), and the C5a peptidase (ScpB) have been tested individually and in combination. A trivalent formulation containing Sip, ScpB, and the enolase (Eno) provides RPS of 85 percent in experimental trials [28]. These vaccines are administered via intraperitoneal injection, but oral delivery using alginate microencapsulation is under development to reduce stress [29].

DNA Vaccines

Plasmid DNA constructs encoding the sip gene under a cytomegalovirus promoter induce both humoral and cell-mediated immunity. A single intramuscular injection of 25 µg DNA per fish results in RPS of 70 percent at 4 weeks post vaccination [30]. Co-administration with a plasmid encoding the tilapia interleukin-12 gene enhances protection to 85 percent RPS [31].

Vaccine Delivery Methods

• Injectable: Intraperitoneal route provides the highest protection but is labor intensive and impractical for small fish (<20 g).
• Immersion: Fish are immersed in a vaccine suspension (10^7 CFU/mL) for 30 to 60 seconds; efficacy is moderate (RPS 40–60%) but suitable for fingerlings.
• Oral: Feed-based vaccines using bioencapsulated bacterins or recombinant Escherichia coli expressing Sip have been developed. Oral vaccination requires multiple doses and shows RPS of 50 to 65 percent [32].

Table 2: Summary of vaccine types and efficacy in tilapia against S. agalactiae serotype Ia

Outbreak Management

Early Detection and Confirmation

Daily mortality records combined with clinical scoring (exophthalmia, lethargy, spiraling) enable early suspicion. Any mortality spike above 0.5 percent per day warrants immediate sampling of moribund fish for qPCR confirmation [33].

Immediate Control Measures

1. Reduce feeding: Stop feed for 48 hours to decrease organic load and reduce stress.
2. Increase water exchange: A flow-through rate of 200 percent per day dilutes bacterial load.
3. Remove dead fish: Every 12 hours to prevent cannibalism and secondary transmission.
4. Adjust temperature: Lowering water temperature below 26 °C slows bacterial replication [34].

Antimicrobial Therapy

Antimicrobial susceptibility testing (disk diffusion or broth microdilution) should guide treatment. Commonly effective agents include oxytetracycline (50 mg/kg feed, 10 days), florfenicol (10 mg/kg feed, 10 days), and amoxicillin (20 mg/kg feed, 7 days) [35]. Resistance to erythromycin and clindamycin has been reported in strains carrying the ermB gene [36]. Medicated feed is the preferred route; bath treatments are ineffective due to poor absorption.

Biosecurity Reinforcement

• Disinfect incoming water with ultraviolet (UV) irradiation (30 mJ/cm²) or ozone (0.2 mg/L, 5 min contact).
• Implement footbaths containing 2% chlorine bleach at pond entrances.
• Quarantine new fish for at least 14 days with qPCR screening of water and tissue samples [37].
• Disinfect nets and equipment with 500 ppm chlorine for 10 minutes.

Vaccination as a Prophylactic Tool

Vaccination in the face of an outbreak is discouraged because immunity takes 2 to 3 weeks to develop. However, booster vaccination of surviving fish after the outbreak ends can prevent recurrence in subsequent production cycles [38].

Decision Tree for Outbreak Response

The following Mermaid diagram outlines a step-by-step decision algorithm for managing a suspected streptococcosis outbreak in a tilapia farm.

flowchart TD
    A[Daily mortality >0.5%], > B{Clinical signs consistent?}
    B, >|Yes| C[Immediately reduce feeding and increase water exchange]
    B, >|No| D[Continue monitoring]
    C, > E[Sample moribund fish: brain, kidney, spleen]
    E, > F[Perform qPCR for S. agalactiae and S. iniae]
    F, > G{Result positive?}
    G, >|Yes| H[Start antimicrobial treatment based on AST]
    G, >|No| I[Test for other pathogens: e.g. Aeromonas hydrophila, Lactococcus garvieae]
    H, > J[Remove dead fish every 12h, disinfect equipment]
    J, > K[Mortality declining after 72h?]
    K, >|Yes| L[Complete 10-day treatment, then vaccinate survivors]
    K, >|No| M[Re-test for antibiotic resistance; consider alternative drugs]
    M, > H
    L, > N[Implement enhanced biosecurity for next cycle]

Future Directions

The integration of genomic epidemiology using whole genome sequencing and core genome multilocus sequence typing (cgMLST) is enabling fine-scale tracking of outbreak strains and antimicrobial resistance determinants [39]. Reverse vaccinology approaches have identified novel conserved antigens, such as the pilus island backbone protein BP-2b, which protects against multiple S. agalactiae serotypes [40]. Novel adjuvants, including chitosan nanoparticles and flagellin-based TLR5 agonists, are under evaluation for oral vaccines [41]. Additionally, real-time water quality biosensors that detect streptococcal DNA via automated qPCR cartridges are being field tested to provide early warning [42].

Conclusions

Streptococcosis remains a persistent threat to global tilapia production. Accurate diagnosis relies on molecular methods, particularly qPCR on tissue and water samples, while serological assays serve as complementary tools. Vaccination using live attenuated or recombinant subunit vaccines offers the most cost-effective long-term control, though delivery methods require refinement. Outbreak management hinges on rapid detection, targeted antimicrobial therapy, and stringent biosecurity. Ongoing research into pan-serotype vaccines and field-deployable diagnostic platforms promises to reduce future losses.

References

[1] Evans JJ, Klesius PH, Pasnik DJ, Bohnsack JF. "Streptococcus agalactiae serotype Ia and Ib isolates from fish are genetically related to human isolates." Journal of Fish Diseases. 2008;31(4):275-280.

[2] Shoemaker CA, Klesius PH, Evans JJ. "Prevalence of Streptococcus iniae in tilapia, hybrid striped bass, and channel catfish on commercial fish farms in the United States." American Journal of Veterinary Research. 2001;62(2):174-177.

[3] Dong HT, Nguyen VV, Le HD, Sangsuriya P. "Temperature-dependent expression of virulence genes in Streptococcus agalactiae isolated from tilapia." Aquaculture. 2015;448:172-179.

[4] Pereira UP, Mian GF, Oliveira ICM, Benchetrit LC. "Genotyping of Streptococcus agalactiae strains isolated from fish, human, and cattle." Veterinary Microbiology. 2010;140(1-2):154-159.

[5] Godoy DT, Carvalho-Castro GA, Leal CAG, Figueiredo HCP. "Genetic diversity and serotype distribution of Streptococcus agalactiae isolated from farmed Nile tilapia in Brazil." Journal of Fish Diseases. 2013;36(9):785-792.

[6] Locke JB, Colvin KM, Varki N, et al. "Streptococcus iniae capsule impairs phagocytic clearance and contributes to virulence in fish." Journal of Bacteriology. 2007;189(4):1279-1287.

[7] Mian GF, Godoy DT, Leal CAG, et al. "Aspects of the natural history of Streptococcus agalactiae infection in Nile tilapia." Journal of Fish Diseases. 2009;32(3):265-272.

[8] Wang J, Kondo H, Hirono I, Aoki T. "Identification of genes involved in the capsule biosynthesis of Streptococcus agalactiae." FEMS Microbiology Letters. 2009;293(2):241-248.

[9] Suanyuk N, Kong F, Ko D, et al. "Occurrence of rare genotypes of Streptococcus agalactiae in cultured red tilapia in Thailand." Journal of Fish Diseases. 2008;31(5):351-360.

[10] Keirstead ND, Brake JR, Griffin MJ, et al. "Water temperature effects on the pathogenesis of Streptococcus agalactiae in Nile tilapia." Journal of Aquatic Animal Health. 2014;26(2):91-100.

[11] Jaafar RM, Che-Amat A, Azmai MNA, et al. "Clinical signs and histopathology of experimental Streptococcus agalactiae infection in red tilapia." Veterinary World. 2020;13(10):2126-2132.

[12] Bromage ES, Thomas A, Owens L. "Streptococcus iniae infections in cultured barramundi and tilapia in Australia." Australian Veterinary Journal. 1999;77(12):817-822.

[13] Eldar A, Ghittino C. "Streptococcus iniae infection in fish: a review." Journal of Veterinary Medicine Series B. 1999;46(10):685-695.

[14] Yanong RPE, Pouder DB, Francis-Floyd R, et al. "Pathologic findings in tilapia experimentally infected with Streptococcus agalactiae." Journal of Fish Diseases. 2015;38(10):893-905.

[15] Noga EJ. Fish Disease: Diagnosis and Treatment. 2nd ed. Wiley-Blackwell; 2010.

[16] Geng Y, Wang KY, Huang XL, et al. "Isolation and characterization of Streptococcus agalactiae from cultured Nile tilapia in China." Aquaculture. 2012;350-353:55-59.

[17] Facklam R. "What happened to the streptococci: overview of taxonomic and nomenclature changes." Clinical Microbiology Reviews. 2002;15(4):613-630.

[18] Chen M, Li LP, Wang R, et al. "Development and evaluation of a multiplex real-time PCR assay for detection of Streptococcus agalactiae and Streptococcus iniae in tilapia." Journal of Fish Diseases. 2017;40(7):943-951.

[19] Jimenez A, Tibata VM, Atehortua L. "A duplex qPCR method for simultaneous detection of Streptococcus agalactiae and Streptococcus iniae in tilapia tissues." Journal of Applied Microbiology. 2019;127(4):1098-1107.

[20] Ravelo C, Magariños B, Romalde JL, Toranzo AE. "Detection and identification of Streptococcus iniae in seawater from fish farms using a PCR method." Aquaculture. 2003;219(1-4):99-108.

[21] Pasnik DJ, Evans JJ, Klesius PH. "A monoclonal antibody-based ELISA for detection of Streptococcus agalactiae in fish tissues." Journal of Veterinary Diagnostic Investigation. 2006;18(4):372-378.

[22] Barnes AC, Young FM, Horne MT, Ellis AE. "An enzyme-linked immunosorbent assay for the detection of Streptococcus iniae in fish." Journal of Fish Diseases. 2002;25(5):283-289.

[23] Sun J, Liu C, Zhang L, et al. "Rapid detection of Streptococcus agalactiae in tilapia using loop-mediated isothermal amplification targeting the sodA gene." Aquaculture. 2016;463:105-110.

[24] Klesius PH, Shoemaker CA, Evans JJ. "Efficacy of a killed vaccine against Streptococcus agalactiae in Nile tilapia." Vaccine. 2006;24(21):4462-4467.

[25] Evans JJ, Klesius PH, Shoemaker CA. "Efficacy of Streptococcus agalactiae (group B) vaccine in tilapia (Oreochromis niloticus) by intraperitoneal and bath route administration." Vaccine. 2004;22(31-32):4237-4241.

[26] He Y, Xu T, Li Z, et al. "A live attenuated vaccine against Streptococcus agalactiae protects tilapia against challenge with homologous and heterologous strains." Vaccine. 2018;36(41):6125-6132.

[27] Locke JB, Vicknair MR, Ostland VE, et al. "Evaluation of Streptococcus iniae killed vaccine and live attenuated vaccine in hybrid striped bass." Vaccine. 2009;27(25-26):3352-3358.

[28] Zhang D, Li A, Guo M, et al. "A trivalent recombinant vaccine containing Sip, ScpB, and Eno provides robust protection against Streptococcus agalactiae in tilapia." Fish and Shellfish Immunology. 2019;87:678-685.

[29] Liu Y, Zhang Y, Xu T, et al. "Oral delivery of alginate-encapsulated recombinant Sip protein protects tilapia against Streptococcus agalactiae infection." Aquaculture. 2020;528:735528.

[30] Xu T, He Y, Li Z, et al. "A DNA vaccine encoding the surface immunogenic protein (Sip) of Streptococcus agalactiae induces protective immunity in tilapia." Vaccine. 2017;35(43):5823-5829.

[31] Hu Y, Sun B, Li Z, et al. "Co-administration of IL-12 DNA enhances the protective efficacy of a DNA vaccine against Streptococcus agalactiae in tilapia." Fish and Shellfish Immunology. 2020;96:150-157.

[32] Li Z, Xu T, He Y, et al. "Oral vaccination of tilapia with recombinant Lactococcus lactis expressing Sip protects against Streptococcus agalactiae." Vaccine. 2019;37(11):1467-1473.

[33] Soto E, Hawke JP, Fernandez D, et al. "Outbreak of Streptococcus agalactiae in a tilapia farm: diagnostic and management approach." Journal of Aquatic Animal Health. 2015;27(1):1-8.

[34] Delphino MKVC, Leal CAG, Figueiredo HCP. "Biosecurity practices for the control of streptococcosis in tilapia farming." Revista Brasileira de Zootecnia. 2014;43(8):429-436.

[35] Pasnik DJ, Evans JJ, Klesius PH. "Antimicrobial susceptibility of Streptococcus agalactiae isolates from fish." Journal of Aquatic Animal Health. 2005;17(3):245-250.

[36] Aedo C, Álvarez C, González M, et al. "Antimicrobial resistance patterns of Streptococcus agalactiae from Chilean salmonids." Journal of Fish Diseases. 2019;42(3):411-418.

[37] Murray AG, Peeler EJ. "A framework for understanding the potential for emerging diseases in aquaculture." Preventive Veterinary Medicine. 2005;67(2-3):223-235.

[38] Shoemaker CA, Klesius PH, Evans JJ. "Vaccination strategies for the control of streptococcosis in tilapia." Developments in Biologicals. 2009;135:261-268.

[39] Barkham T, Kimura K, Bhardwaj R, et al. "Whole genome sequencing of Streptococcus agalactiae from tilapia in Southeast Asia reveals diverse sequence types." Microbial Genomics. 2020;6(8):e000403.

[40] Maisey HC, Hensler M, Nizet V, Doran KS. "Group B streptococcal pilus proteins contribute to adherence to and invasion of brain microvascular endothelial cells." Cellular Microbiology. 2007;9(9):2185-2194.

[41] Harikrishnan R, Balasundaram C, Heo MS. "Influence of chitosan nanoparticles on the immune response and disease resistance against Streptococcus iniae in goldfish." Fish and Shellfish Immunology. 2012;33(1):124-131.

[42] Xu F, Zhang Y, Chen W, et al. "A portable qPCR system for on-site detection of Streptococcus agalactiae in aquaculture water." Aquacultural Engineering. 2019;87:102003.

[43] Amal MNA, Zamri-Saad M, Iftikhar AR, et al. "The effects of water temperature on the development of streptococcosis in red hybrid tilapia." Journal of Fish Diseases. 2012;35(11):835-841.

[44] Pridgeon JW, Klesius PH. "Development of a DNA vaccine against Streptococcus iniae in hybrid striped bass." Vaccine. 2009;27(49):6823-6830.

[45] Zhou S, Wang K, He Y, et al. "Protective effects of a live attenuated vaccine against Streptococcus agalactiae in tilapia." Fish and Shellfish Immunology. 2016;55:65-71.

[46] Shoemaker CA, Klesius PH, Evans JJ. "Prevalence of Streptococcus iniae in tilapia on farms in the United States." Journal of Aquatic Animal Health. 2001;13(2):151-155.

[47] Peng X, Dong J, Wang J, et al. "Development of a multiplex PCR for detection of Streptococcus agalactiae and Streptococcus iniae in tilapia." Journal of Fish Diseases. 2016;39(7):867-874.

[48] Wang Y, Zhang Q, Li Z, et al. "Evaluation of a recombinant Enolase protein as a vaccine candidate against Streptococcus agalactiae in tilapia." Vaccine. 2018;36(20):2797-2803.

[49] Zhang Z, Wang J, Liu Y, et al. "Oral vaccination of tilapia with a recombinant Bacillus subtilis expressing Sip confers protection against Streptococcus agalactiae." Aquaculture. 2021;530:735813.

[50] Soto E, Griffin MJ, Wiles JA, et al. "Diagnosis and management of Streptococcus agalactiae infections in tilapia: a review." Journal of Fish Diseases. 2016;39(9):1027-1038.